Mary J Newman

US Patent:

7101916, Sep 5, 2006

Filed:

May 19, 2003

Appl. No.:

10/441947

Inventors:

Douglas Shytle - Lutz FL, US
Paul Sanberg - Spring Hill FL, US
Mary Newman - Valrico FL, US
Archie A. Silver - Tampa FL, US

Assignee:

University of South Florida - Tampa FL

International Classification:

A61K 31/13

US Classification:

514661, 514660

Abstract:

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0. 5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depressoin, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

US Patent:

8026283, Sep 27, 2011

Filed:

Jan 4, 2010

Appl. No.:

12/651813

Inventors:

Douglas Shytle - Lutz FL, US
Paul Sanberg - Spring Hill FL, US
Mary Newman - Valrico FL, US
Archie A. Silver - Tampa FL, US

Assignee:

University of South Florida - Tampa FL

International Classification:

A61K 31/13

US Classification:

514661

Abstract:

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0. 5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

US Patent:

20020016370, Feb 7, 2002

Filed:

Jun 15, 2001

Appl. No.:

09/882934

Inventors:

Douglas Shytle - Lutz FL, US
Paul Sanberg - Spring Hill FL, US
Mary Newman - Valrico FL, US
Archie Silver - Tampa FL, US

International Classification:

A61K031/13
C07C211/34

US Classification:

514/661000, 564/460000

Abstract:

A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

US Patent:

20020016371, Feb 7, 2002

Filed:

Jun 15, 2001

Appl. No.:

09/882935

Inventors:

Douglas Shytle - Lutz FL, US
Paul Sanberg - Spring Hill FL, US
Mary Newman - Valrico FL, US
Archie Silver - Tampa FL, US

International Classification:

A61K031/13
C07C211/34

US Classification:

514/661000, 564/460000

Abstract:

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

US Patent:

20060276551, Dec 7, 2006

Filed:

Apr 5, 2006

Appl. No.:

11/278770

Inventors:

Douglas Shytle - Lutz FL, US
Paul Sanberg - Spring Hill FL, US
Mary Newman - Valrico FL, US
Archie Silver - Tampa FL, US

International Classification:

A61K 31/13

US Classification:

514663000

Abstract:

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer) atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depressoin, an anxiety disorder, schizophrenia, a seizure disorder. Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome. Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

US Patent:

20110028565, Feb 3, 2011

Filed:

Sep 21, 2010

Appl. No.:

12/886887

Inventors:

Douglas Shytle - Lutz FL, US
Paul Sanberg - Spring Hill FL, US
Mary Newman - Valrico FL, US
Archie A. Silver - Tampa FL, US

Assignee:

University of South Florida - Tampa FL

International Classification:

A61K 31/13

US Classification:

514661

Abstract:

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

US Patent:

20170181983, Jun 29, 2017

Filed:

Mar 13, 2017

Appl. No.:

15/456934

Inventors:

DOUGLAS SHYTLE - LARGO FL, US
PAUL R. SANBERG - SPRING HILL FL, US
MARY NEWMAN - VALRICO FL, US
ARCHIE A. SILVER - TAMPA FL, US

Assignee:

UNIVERSITY OF SOUTH FLORIDA - TAMPA FL

International Classification:

A61K 31/13
A61K 9/00

Abstract:

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depressoin, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.